The Role of Appetite Stimulants for Cancer-Related Weight Loss
Involuntary weight loss and its end-stage manifestation, the anorexia and cachexia syndrome, is a frequent complication of cancer. The incidence of weight loss varies both with the primary site of the malignancy and its stage. At presentation, 15–48% of cancer patients report weight loss, while more than 80% of those with advanced disease note involuntary weight loss . A weight loss of as little as 5% from premorbid weight predicts a poor prognosis, particularly among patients with lymphoma, lung, breast or gastrointestinal malignancies. Weight loss of less than 5% adversely impacts survival, with the greatest effect seen in those patients with good performance status . Involuntary weight loss adversely affects quality of life as well  .
KeywordsClin Oncol Terminal Cancer Patient Methylprednisolone Sodium Succinate Appetite Stimulant Appetite Stimulation
Unable to display preview. Download preview PDF.
- 2.MacDonald N, Baracos VE, Plata-Salaman CR, Tisdale MJ (2000) Cachexia-anorexia workshop. Vancouver, British Columbia, Canada. November 7-9-1997. Nutrition 16:1006–1020Google Scholar
- 5.Bruera E, Fainsinger RL (1993) Clinical management of cachexia and anorexia. In: Doyle D, Hanks G, MacDonald N (eds) Oxford textbook of palliative medicine. Oxford Medical Publications, London, pp 330–337Google Scholar
- 8.Wilcox JC, Corr J, Shaw J (1984) Prednisone as an appetite stimulant in patients with cancer. BMJ 288:27Google Scholar
- 11.Popiela T, Lucchi R, Giongo F ( 1989) Methylprednisolone as palliative therapy for female terminal cancer patients. Eur J Cancer Clin Oncol 25:1923–1929Google Scholar
- 14.Wadleigh R, Spaulding M, Lembersky B et al (1990) Dronabinol enhancement of appetite in cancer patients. Proc Am Soc Clin Oncol 9:331 (Abs 1280)Google Scholar
- 30.Von Roenn JH, Armstrong D, Kotier DP et al (1994) Megestrol acetate in patients with AIDS-related cachexia. Ann Int Med 121:393–399Google Scholar